Inclusion Criteria:

- Patients with newly diagnosed AML, classified by FAB criteria

- Age not superior to 60 years

- Verbal informed consent for the chemotherapy and written for the mobilization and
stem cell transplantation

Exclusion Criteria:

- Patients treated previously for its AML with other chemotherapy different from
hydroxyurea

- Acute promyelocytic leukemia (M3)

- Chronic myeloid leukemia in blastic crisis

- Leukemias appearing after other myeloproliferative processes

- Leukemias surviving after myelodysplastic syndromes with more than 6 months of
evolution

- Presence of other neoplastic disease in activity

- Secondary AML which had appeared after cured malignancies (for instance Hodgkin
disease) and those who are still exposed to alkylant agents or radiation

- Renal and hepatic abnormal function with creatinine values and/or bilirubin two times
higher than the normal threshold, except when this alteration could be attributed to
the leukemia

- Patients with a fraction of ejection very low (inferior to 40%), symptomatic cardiac
insufficiency or both

- Patients with a grave concomitant neurological or psychiatric disease

- Positivity of HIV (donor and/or receptor)